The synthetic SA/IBR/EPG selectively delivered IBR to TAMs and blocked BTK activation, thus inhibiting Th2 tumor-promoting cytokine release and reducing tumor volume and angiogenesis [25]. The gene discussed is BTK; the disease is neoplasm.